Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC46H43F3N6O7 |
InChIKeyVWGOZKTYUULSHB-XLYAUNJQSA-N |
CAS Registry2971850-28-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 15 Sep 2023 | |
Neoplasms | Preclinical | US | 15 Sep 2023 |